Anti-inflammatory, antibacterial and immunomodulatory treatment in children with symptoms corresponding to the research condition PANS (Pediatric Acute-onset Neuropsychiatric Syndrome): A systematic review
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
Objective: To assess effects of treatment against a hypothesized neuroinflammation in children with symptoms corresponding to the research condition Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) which is not included in current diagnostic systems. Methods: Systematic literature searches were performed (1998 to June 2020) in PubMed, Embase, the Cochrane Library, CINAHL, PsycInfo, and HTA databases. Inclusion criteria: patients (P) were children (<18 years) with PANS; intervention (I)/comparison (C) was use of, versus no use of, anti-inflammatory, antibacterial or immunomodulating treatments; outcomes (O) were health-related quality of life (HRQL), level of functioning, symptom change, and complications. Results: Four randomised controlled trials (RCTs) and three non-RCTs, including 23 to 98 patients, fulfilled the PICO. HRQL was not investigated in any study. Regarding level of functioning, two RCTs investigated antibiotics (penicillin V, azithromycin) and one RCT investigated immunomodulating treatments (intravenous immunoglobulins (IVIG), plasma exchange). Regarding symptoms, two non-RCTs investigated anti-inflammatory treatment (cyclooxygenase (COX) inhibitors, corticosteroids), two RCTs and one non-RCT investigated antibiotics (penicillin V, azithromycin), and two RCTs investigated immunomodulating treatments (IVIG, plasma exchange). Complications, reported in five studies, were consistent with those listed in the summary of products characteristics (SPC). All studies were assessed to have some or major problems regarding directness, the absence of an established diagnosis contributing to clinical diversity in the studied populations. All studies were assessed to have major risk of bias, including selection and detection biases. Due to clinical and methodological diversity, meta-analyses were not performed. Conclusion: This systematic review reveals very low certainty of evidence of beneficial effects, and moderate certainty of evidence of adverse effects, of anti-inflammatory, antibacterial or immunomodulating treatments in patients with symptoms corresponding to the research condition PANS. Available evidence neither supports nor excludes potential beneficial effects, but supports that such treatment can result in adverse effects. Registration: PROSPERO (CRD42020155714).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A systematic analysis from 2021 of randomized controlled trials for IAE anti-inflammatory, antibacterial, or immunomodulating treatment found very low certainty of evidence in their beneficial effects whereas there was moderate certainty of evidence for adverse effects.50”
From An updated review of pediatric autoimmune neuropsychiatric disorders associated with Streptococcus/pediatric acute-onset neuropsychiatric syndrome, also known as idiopathic autoimmune encephalitis: What the allergist should know (2023) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests there is a need for additional larger, welldesigned studies of well characterized patients with IAE, to determine specific biomarkers that could identify those patients most likely to benefit from these therapies.”
From An updated review of pediatric autoimmune neuropsychiatric disorders associated with Streptococcus/pediatric acute-onset neuropsychiatric syndrome, also known as idiopathic autoimmune encephalitis: What the allergist should know (2023) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 6×
“In the GRADE assessment regarding antibiotics and level of functioning, we downgraded three steps because of risk of bias (uncertainties regarding the PLOS ONE | https://doi.org/10.1371/journal.pone.0253844 July 1, 2021 4 / 15 comparability of the groups, unblinding due to adverse reactions, multiple comparisons, uncl…”
MethodInfluentialMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Swedo, S. E., Leonard, H. L., Garvey, M., Mittleman, B., Allen, A. J., Perlmutter, S., Dow, S., Zamkoff, J., Dubbert, B. K., & Lougee, L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.2.264 · Cited by 1,534 · cited 6×
“It was also difficult to distinguish the onset of tics in the PANDAS group from the non-PANDAS tic disorders.”
BackgroundInfluentialPerlmutter, S. J., Leitman, S. F., Garvey, M. A., Hamburger, S., Feldman, E., Leonard, H. L., & Swedo, S. E. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12297-3 · Cited by 556 · cited 8×
“Indeed, in both IVIG trials, vomiting occurred only in the intervention group [25, 26].”
BackgroundResultInfluentialRingold, S., Angeles‐Han, S. T., Beukelman, T., Lovell, D., Cuello, C. A., Becker, M. L., Colbert, R. A., Feldman, B. M., Ferguson, P. J., Gewanter, H., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23870 · Cited by 462
E. Swedo, S. (2012) · Pediatrics & Therapeutics · doi:10.4172/2161-0665.1000113 · Cited by 421 · cited 3×
“Therefore, in 2012 a group of clinicians and researchers proposed a purely symptom-based entity called Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), based on the clinical descriptions of 400 patients [9].”
BackgroundChang, K., Frankovich, J., Cooperstock, M., Cunningham, M. W., Latimer, M. E., Murphy, T. K., Pasternack, M., Thienemann, M., Williams, K., Walter, J., et al. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0084 · Cited by 359 · cited 18×
“This systematic review, based on seven studies with major risk of bias and problems regarding directness and precision, shows that conclusive evidence is largely lacking regarding potential beneficial effects of anti-inflammatory, antibiotic and immunomodulatory treatments for children and adolescents with symptoms co…”
BackgroundInfluentialSydenham's chorea. A model for childhood autoimmune neuropsychiatric disorders
Swedo, S. E. (1994) · JAMA · doi:10.1001/jama.272.22.1788 · Cited by 285
Garvey, M. A., Perlmutter, S. J., Allen, A. J., Hamburger, S., Lougee, L., Leonard, H. L., Witowski, M. E., Dubbert, B., & Swedo, S. E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00020-7 · Cited by 250 · cited 4×
“Regarding directness, the studies had major [22] or some [20, 21, 23–26] problems.”
BackgroundMethodInfluentialSnider, L. A., Lougee, L., Slattery, M., Grant, P., & Swedo, S. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.035 · Cited by 237
Cited by
Pediatric Acute-Onset Neuropsychiatric Syndrome: Current Perspectives
Gagliano, A., Carta, A., Tanca, M. G., & Sotgiu, S. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s362202 · Cited by 48
“Plasmapheresis or Plasma Exchange (PE) The first randomized clinical trial has been conducted in children with infection-triggered OCD and tic disorders, comparing PE with IVIG and placebo.(137) Plasma exchange and IVIG both resulted effective in the reduction of symptom”
BackgroundXu, J., Frankovich, J., Liu, R.-J., Thienemann, M., Silverman, M. A., Farhadian, B., Willett, T. A., Manko, C., Columbo, L. A., Leibold, C. M., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.07.044 · Cited by 31
Conti, F., Moratti, M., Leonardi, L., Catelli, A., Bortolamedi, E., Filice, E., Fetta, A., Fabi, M., Facchini, E., Cantarini, M. E., et al. (2023) · Cells · doi:10.3390/cells12192417 · Cited by 33
Ma, M., Masterson, E. E., Gao, J., Karpel, H. C., Chan, A. L., Pooni, R., Sandberg, J. K., Rubesova, E., Farhadian, B., Willett, T. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21688 · Cited by 26
Neuroinflammation in Obsessive-Compulsive Disorder
Vreeland, A., Thienemann, M., Cunningham, M. W., Muscal, E., Pittenger, C., & Frankovich, J. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.11.004 · Cited by 22
Hajjari, P., Oldmark, M. H., Fernell, E., Jakobsson, K., Vinsa, I., Thorsson, M., Monemi, M., Stenlund, L., Fasth, A. L., Furuhjelm, C., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04181-x · Cited by 16
“Antibiotics, nonsteroid anti-inflammatory drugs (NSAIDs), corticosteroids, plasmapheresis, and intravenous immunoglobulin (IVIG) have also been proposed [10], but here too, more in-depth research and prospective long-term outcome follow-up is needed [11, 12].”
BackgroundSelf-citationUK research priority setting for childhood neurological conditions
Cadwgan, J., Goodwin, J., Babcock, B., Brick, M., Chin, R., Easton, A., Green, B., Hannan, S., Inward, R. P. D., Kinsella, S., et al. (2024) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.16021 · Cited by 14
Neuroinflammatory syndromes in children
Hauptman, A. J., & Ferrafiat, V. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000846 · Cited by 10
Hoffman, K. L., & Cano-Ramírez, H. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2074396 · Cited by 12
“However, Johnson et al [30] concluded that evidence from more carefully-designed clinical studies would be necessary in order to unequivocally establish a clear risk/benefit profile of such treatments.”
BackgroundInfluentialHan, V. X., Nishida, H., Keating, B. A., Gloss, B., Lau, X., Dissanayake, R., Hayes, J. P., Mohammad, S. S., Patel, S., & Dale, R. C. (2025) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200467 · Cited by 9
Hardin, H., Shao, W., & Bernstein, J. A. (2023) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2023.08.022 · Cited by 10
Matera, M., Biagioli, V., Illiceto, M. T., Palazzi, C. M., Cavecchia, I., Manzi, A., Lugli, S., Pennazzi, L., Meocci, M., Pedaci, F. A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1726630 · Cited by 7
Tagi, V. M., Tosi, M., Greco, I. P., Stucchi, E., Verduci, E., & Zuccotti, G. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1477893 · Cited by 8
Andersson, P. S. G., Wachtel, L. E., Lundberg, J., Jamshidi, E., Bring, J., Rask‐Andersen, M., Jarbin, H., Jokinen, J., & Boström, A. E. D. (2022) · npj Mental Health Research · doi:10.1038/s44184-022-00013-8 · Cited by 4
Dale, R. C., & Patel, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00140-2 · Cited by 2
“It Doesn’t Matter Where OCD Comes From,” or Does It?
Pinciotti, C. M., McCarty, R. J., & Ponzini, G. T. (2026) · Current Psychiatry Reports · doi:10.1007/s11920-026-01708-x · Cited by 1
“However, the evidence base is limited: a systematic review found “very low” certainty for the benefits of these adjunctive approaches in PANS-like presentations [ 109].”
Georgiou, A. N., Voskarides, K., Zanos, P., & Chatzittofis, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1379922 · Cited by 2
Han, V. X., Nishida, H., Keating, B. A., Gloss, B., Lau, X., Dissanayake, R., Hayes, J. P., Mohammad, S. S., Patel, S., & Dale, R. C. (2025) · medRxiv · doi:10.1101/2025.03.27.25324808 · Cited by 1
PANDAS: behov for nasjonale retningslinjer
Berger, M. F., Aarli, Å., & Griffiths, S. T. (2021) · Tidsskrift for Norsk psykologforening · doi:10.52734/5tfiz496
AAPdN virtual conference – Accepted abstracts.
Aylward, S. A. (2022) · Journal of Pediatric Neuropsychology · doi:10.1007/s40817-022-00122-4
“In stark contrast, even with treatment, most children diagnosed with CO-OCD maintain an OCD diagnosis in adulthood (Rough et al., 2020).”
BackgroundInfluentialEllul, P., & Peyre, H. (2023) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2023.01.005
Álvarez-Torres, E., Ojeda-Bonilla, S. V., Marrero, N. E. R., & Figueroa-Amaro, J. (2025) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2025.148053
Calaprice, D., Moon, C., Helvick, M., Harvey, C. A., Tang, A. W., Aguirre, K., Tererri, R., Hunt, J., Whitty, C., & Fitzgerald, M. (2026) · Journal of Child and Adolescent Psychopharmacology · doi:10.1177/10445463261440137
Lim, E., Cheng, N. C. L., & Lim, C. E. D. (2026) · Infectious Disease Reports · doi:10.3390/idr18040069
Metadata
- Authors
- Johnson, M., Ehlers, S., Fernell, E., Hajjari, P., Wartenberg, C., & Wallerstedt, S. M.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Kungälvs Sjukhus (SE)
- Corresponding author
- Johnson, Mats
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-07-01
- Volume
- 16
- Issue
- 7
- Pages
- e0253844
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8248649
- OpenAlex
- W3175116915
- Cited by
- 25
- References
- 36
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 2
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Kawasaki Disease and Coronary Complications
- Keywords
- pediatric acute-onset neuropsychiatric syndrome, PANS, anti-inflammatory therapy, antibiotic therapy, immunomodulatory therapy, neuroinflammation, children, intravenous immunoglobulin, plasma exchange, antibiotics, penicillin V, azithromycin, corticosteroids, cyclooxygenase inhibitors, health-related quality of life, treatment side effects
- MeSH terms
- Anti-Inflammatory Agents, Anti-Bacterial Agents, Autoimmune Diseases, Child, Combined Modality Therapy, Glucocorticoids, Humans, Immunologic Factors, Obsessive-Compulsive Disorder, Plasma Exchange, Quality of Life, Randomized Controlled Trials as Topic, Immunoglobulins, Intravenous, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.